MGC Pharmaceuticals Ltd 72.5% potential upside indicated by Canaccord Genuity

MGC Pharmaceuticals Ltd with ticker (LON:MXC) now has a potential upside of 72.5% according to Canaccord Genuity.



Canaccord Genuity set a target price of 2 GBX for the company, which when compared to the MGC Pharmaceuticals Ltd share price of 1 GBX at opening today (23/03/2023) indicates a potential upside of 72.5%. Trading has ranged between (52 week low) and 2 (52 week high) with an average of 3,034,166 shares exchanging hands daily. The market capitalisation at the time of writing is £40,990,201.

MGC Pharmaceuticals Ltd is an Australia-based biopharma company. The Company is primarily focused on the development and supply of standardized phytomedicines to patients globally. It has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The Company is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. It has a product offering targeting two medical conditions, which include epilepsy and dementia. The Company’s wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.